Evidence map›Paper›PMID 31294646›Full record

ArticleJournal of psychopharmacology (Oxford, England)2019

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.

Jacobi I Cunningham, David J Eyerman, Mark S Todtenkopf, Reginald L Dean, Daniel R Deaver, Connie Sanchez, Mark Namchuk

Open access · hybridAbstract read
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jacobi I CunninghamAlkermes, Inc., Waltham, MA, USA.ORCID 0000-0003-4217-1927
David J EyermanAlkermes, Inc., Waltham, MA, USA.
Mark S TodtenkopfAlkermes, Inc., Waltham, MA, USA.
Reginald L DeanAlkermes, Inc., Waltham, MA, USA.
Daniel R DeaverAlkermes, Inc., Waltham, MA, USA.
Connie SanchezAlkermes, Inc., Waltham, MA, USA.
Mark NamchukAlkermes, Inc., Waltham, MA, USA.
Alkermes (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlanzapine, regarded as one of the most efficacious antipsychotic medications for the treatment of schizophrenia, is associated with a high risk of weight gain and metabolic dysfunction. ALKS 3831, a clinical candidate for treatment of schizophrenia, is a combination of olanzapine and samidorphan, an opioid receptor antagonist. The addition of samidorphan is intended to mitigate weight gain and the metabolic dysregulation associated with the use of olanzapine.

methodsNon-clinical studies were conducted to assess the metabolic effects of olanzapine and samidorphan alone and in combination at clinically relevant exposure levels.

resultsChronic olanzapine administration in male and female rats shifted body composition by increasing adipose mass, which was accompanied by an increase in the rate of weight gain in female rats. Co-administration of samidorphan normalized body composition in both sexes and attenuated weight gain in female rats. In hyperinsulinemic euglycemic clamp experiments conducted prior to measurable changes in weight and/or body composition, olanzapine decreased hepatic insulin sensitivity and glucose uptake in muscle while increasing uptake in adipose tissue. Samidorphan appeared to normalize glucose utilization in both tissues, but did not restore hepatic insulin sensitivity. In subsequent studies, samidorphan normalized olanzapine-induced decreases in whole-body glucose clearance following bolus insulin administration. Results from experiments in female monkeys paralleled the effects in rats.

conclusionsOlanzapine administration increased weight gain and adiposity, both of which were attenuated by samidorphan. Furthermore, the combination of olanzapine and samidorphan prevented olanzapine-induced insulin insensitivity. Collectively, these data indicate that samidorphan mitigates several metabolic abnormalities associated with olanzapine in both the presence and the absence of weight gain.

Indexed as

Glucose Metabolism DisordersAdipose TissueAnimalsAntipsychotic AgentsDrug CombinationsFemaleMacaca fascicularisMaleNaltrexoneNarcotic AntagonistsOlanzapineRatsRats, Sprague-DawleySex FactorsWeight Gain3-carboxamido-4-hydroxynaltrexoneAntipsychotic AgentsDrug CombinationsNaltrexoneNarcotic AntagonistsOlanzapineatypical antipsychoticmetabolic dysfunctionOlanzapineopioidweight gain

Identifiers

PMID31294646
PMCPMC6764014
OpenAlexW2958585267

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.